CA2266028A1 - Compositions buccales contenant du fluocinonure - Google Patents
Compositions buccales contenant du fluocinonure Download PDFInfo
- Publication number
- CA2266028A1 CA2266028A1 CA002266028A CA2266028A CA2266028A1 CA 2266028 A1 CA2266028 A1 CA 2266028A1 CA 002266028 A CA002266028 A CA 002266028A CA 2266028 A CA2266028 A CA 2266028A CA 2266028 A1 CA2266028 A1 CA 2266028A1
- Authority
- CA
- Canada
- Prior art keywords
- oral
- composition
- glyceryl monooleate
- fluocinonide
- gingivitis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 29
- WJOHZNCJWYWUJD-IUGZLZTKSA-N Fluocinonide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)COC(=O)C)[C@@]2(C)C[C@@H]1O WJOHZNCJWYWUJD-IUGZLZTKSA-N 0.000 title claims abstract description 26
- 229960000785 fluocinonide Drugs 0.000 title claims abstract description 26
- 239000000263 2,3-dihydroxypropyl (Z)-octadec-9-enoate Substances 0.000 claims abstract description 25
- RZRNAYUHWVFMIP-GDCKJWNLSA-N 3-oleoyl-sn-glycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](O)CO RZRNAYUHWVFMIP-GDCKJWNLSA-N 0.000 claims abstract description 25
- RZRNAYUHWVFMIP-UHFFFAOYSA-N monoelaidin Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-UHFFFAOYSA-N 0.000 claims abstract description 25
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 21
- 208000007565 gingivitis Diseases 0.000 claims abstract description 18
- 230000003902 lesion Effects 0.000 claims abstract description 17
- 206010028034 Mouth ulceration Diseases 0.000 claims abstract description 16
- 238000011282 treatment Methods 0.000 claims abstract description 16
- 208000025865 Ulcer Diseases 0.000 claims abstract description 13
- 231100000397 ulcer Toxicity 0.000 claims abstract description 13
- 206010061218 Inflammation Diseases 0.000 claims abstract description 12
- 230000004054 inflammatory process Effects 0.000 claims abstract description 12
- 210000000214 mouth Anatomy 0.000 claims abstract description 12
- 208000029505 oral erosive lichen Diseases 0.000 claims abstract description 9
- 230000000699 topical effect Effects 0.000 claims abstract description 9
- 206010034277 Pemphigoid Diseases 0.000 claims abstract description 8
- 208000009299 Benign Mucous Membrane Pemphigoid Diseases 0.000 claims abstract description 6
- 208000012192 Mucous membrane pemphigoid Diseases 0.000 claims abstract description 6
- 201000010002 cicatricial pemphigoid Diseases 0.000 claims abstract description 6
- 230000001496 desquamative effect Effects 0.000 claims abstract description 6
- 230000003232 mucoadhesive effect Effects 0.000 claims abstract description 6
- 208000002399 aphthous stomatitis Diseases 0.000 claims abstract description 5
- 201000011486 lichen planus Diseases 0.000 claims abstract description 5
- 208000005522 Orofacial Granulomatosis Diseases 0.000 claims abstract description 4
- 201000010099 disease Diseases 0.000 claims abstract description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 4
- 208000014996 oral Crohn disease Diseases 0.000 claims abstract description 4
- 208000003265 stomatitis Diseases 0.000 claims abstract description 4
- 206010028116 Mucosal inflammation Diseases 0.000 claims abstract description 3
- 201000010927 Mucositis Diseases 0.000 claims abstract description 3
- RZRNAYUHWVFMIP-KTKRTIGZSA-N 1-oleoylglycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-KTKRTIGZSA-N 0.000 claims description 15
- RZRNAYUHWVFMIP-HXUWFJFHSA-N glycerol monolinoleate Natural products CCCCCCCCC=CCCCCCCCC(=O)OC[C@H](O)CO RZRNAYUHWVFMIP-HXUWFJFHSA-N 0.000 claims description 15
- 229940074096 monoolein Drugs 0.000 claims description 15
- 239000003814 drug Substances 0.000 claims description 10
- 238000002360 preparation method Methods 0.000 claims description 10
- 239000012188 paraffin wax Substances 0.000 claims description 8
- 210000000088 lip Anatomy 0.000 claims description 7
- 210000005178 buccal mucosa Anatomy 0.000 claims description 6
- 210000003254 palate Anatomy 0.000 claims description 5
- 238000011321 prophylaxis Methods 0.000 claims description 5
- 210000002105 tongue Anatomy 0.000 claims description 4
- 210000004877 mucosa Anatomy 0.000 claims description 3
- 238000000034 method Methods 0.000 claims description 2
- 210000002200 mouth mucosa Anatomy 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 239000012049 topical pharmaceutical composition Substances 0.000 claims 1
- 230000002035 prolonged effect Effects 0.000 abstract description 3
- 239000000499 gel Substances 0.000 description 6
- 239000000853 adhesive Substances 0.000 description 5
- 230000001070 adhesive effect Effects 0.000 description 5
- 238000013268 sustained release Methods 0.000 description 5
- 239000012730 sustained-release form Substances 0.000 description 5
- 239000013543 active substance Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000001993 wax Substances 0.000 description 4
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 239000004215 Carbon black (E152) Substances 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 229930195733 hydrocarbon Natural products 0.000 description 3
- 150000002430 hydrocarbons Chemical class 0.000 description 3
- 239000002324 mouth wash Substances 0.000 description 3
- 210000004400 mucous membrane Anatomy 0.000 description 3
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 2
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 2
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 2
- 239000005642 Oleic acid Substances 0.000 description 2
- 208000007117 Oral Ulcer Diseases 0.000 description 2
- 208000025157 Oral disease Diseases 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 230000003444 anaesthetic effect Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 208000002352 blister Diseases 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 239000003246 corticosteroid Substances 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 230000003628 erosive effect Effects 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 239000010408 film Substances 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 125000005456 glyceride group Chemical group 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 2
- 239000007937 lozenge Substances 0.000 description 2
- 229940051866 mouthwash Drugs 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- 239000003605 opacifier Substances 0.000 description 2
- 229940067003 orabase Drugs 0.000 description 2
- 206010030983 oral lichen planus Diseases 0.000 description 2
- 208000028169 periodontal disease Diseases 0.000 description 2
- 230000003239 periodontal effect Effects 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000008719 thickening Effects 0.000 description 2
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 1
- HNNIWKQLJSNAEQ-UHFFFAOYSA-N Benzydamine hydrochloride Chemical compound Cl.C12=CC=CC=C2C(OCCCN(C)C)=NN1CC1=CC=CC=C1 HNNIWKQLJSNAEQ-UHFFFAOYSA-N 0.000 description 1
- 241000197194 Bulla Species 0.000 description 1
- BQENDLAVTKRQMS-SBBGFIFASA-L Carbenoxolone sodium Chemical compound [Na+].[Na+].C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C([O-])=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](OC(=O)CCC([O-])=O)C1(C)C BQENDLAVTKRQMS-SBBGFIFASA-L 0.000 description 1
- 239000004099 Chlortetracycline Substances 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000035874 Excoriation Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 1
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 1
- 206010024438 Lichenification Diseases 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- 206010033733 Papule Diseases 0.000 description 1
- 208000005888 Periodontal Pocket Diseases 0.000 description 1
- 206010037888 Rash pustular Diseases 0.000 description 1
- 230000001760 anti-analgesic effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000010385 ascorbyl palmitate Nutrition 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229960001689 benzydamine hydrochloride Drugs 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 229960002252 carbenoxolone sodium Drugs 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- CYDMQBQPVICBEU-UHFFFAOYSA-N chlorotetracycline Natural products C1=CC(Cl)=C2C(O)(C)C3CC4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O CYDMQBQPVICBEU-UHFFFAOYSA-N 0.000 description 1
- 229960004475 chlortetracycline Drugs 0.000 description 1
- CYDMQBQPVICBEU-XRNKAMNCSA-N chlortetracycline Chemical compound C1=CC(Cl)=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O CYDMQBQPVICBEU-XRNKAMNCSA-N 0.000 description 1
- 235000019365 chlortetracycline Nutrition 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229960003943 hypromellose Drugs 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 229960004393 lidocaine hydrochloride Drugs 0.000 description 1
- YECIFGHRMFEPJK-UHFFFAOYSA-N lidocaine hydrochloride monohydrate Chemical compound O.[Cl-].CC[NH+](CC)CC(=O)NC1=C(C)C=CC=C1C YECIFGHRMFEPJK-UHFFFAOYSA-N 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229960000282 metronidazole Drugs 0.000 description 1
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- -1 monoolein Chemical compound 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000003961 penetration enhancing agent Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 208000029561 pustule Diseases 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 150000003873 salicylate salts Chemical class 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 229960005294 triamcinolone Drugs 0.000 description 1
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1274—Non-vesicle bilayer structures, e.g. liquid crystals, tubules, cubic phases or cochleates; Sponge phases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physiology (AREA)
- Dispersion Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nutrition Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Cette composition topique contient du fluocinonure dans une base de mono-oléate de glycéryle présentant une teneur en eau inférieure à environ 20 % en poids du poids de la composition, et elle est destinée au traitement d'ulcérations, d'inflammations et de lésions de la cavité buccale. On étale sur une ulcération une mince couche de cette composition, laquelle forme un film qui adhère très bien à la muqueuse et maintient le fluocinonure en contact avec l'ulcération pendant une période prolongée. Cette composition est notamment utile pour le traitement d'aphtes buccaux, de l'inflammation d'une muqueuse (en particulier mucositis neuroticans agranulocytica), de la maladie de Crohn à localisation buccale, de la granulomatose bucco-faciale, de la pemphigoïde cicatricielle, du lichen plan érosif, de la gingivite telle que la gingivite desquamative et la gingivite associée au lichen plan, ainsi que des maladies vésiculo-érosives buccales.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9618964.2A GB9618964D0 (en) | 1996-09-11 | 1996-09-11 | Oral composition |
| GB9618964.2 | 1996-09-11 | ||
| PCT/EP1997/004820 WO1998010770A1 (fr) | 1996-09-11 | 1997-09-05 | Compositions buccales contenant du fluocinonure |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2266028A1 true CA2266028A1 (fr) | 1998-03-19 |
Family
ID=10799761
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002266028A Abandoned CA2266028A1 (fr) | 1996-09-11 | 1997-09-05 | Compositions buccales contenant du fluocinonure |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP0973525A1 (fr) |
| JP (1) | JP2001505544A (fr) |
| AU (1) | AU4301597A (fr) |
| CA (1) | CA2266028A1 (fr) |
| GB (1) | GB9618964D0 (fr) |
| WO (1) | WO1998010770A1 (fr) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1368874A (zh) * | 1999-08-06 | 2002-09-11 | 马克斯－德尔布吕克分子医学研究所 | 可植入的生物活性物质储存体 |
| AU2001278516A1 (en) * | 2000-08-07 | 2002-02-18 | Unilever Plc | Oral cosmetic composition comprising petroleum jelly enrobing an active agent |
| US20080219935A1 (en) * | 2005-07-08 | 2008-09-11 | Sang-Hoon Kwak | Phase Transitive Breath Care Products |
| US10111956B2 (en) | 2013-06-03 | 2018-10-30 | Tolmar, Inc. | Corticosteroid compositions |
| CA2912873A1 (fr) * | 2013-06-03 | 2014-12-11 | Tolmar, Inc. | Compositions de corticosteroides |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS58225009A (ja) * | 1982-06-23 | 1983-12-27 | Shionogi & Co Ltd | コルチコステロイド外用製剤 |
| EP0187433B1 (fr) * | 1983-08-01 | 1990-12-27 | Teijin Limited | Composition pharmaceutique poudreuse pour l'application sur la muqueuse de la cavité orale ou nasale |
| US5061700A (en) * | 1989-11-16 | 1991-10-29 | Gordon Jay Dow | Glyceryl acetate ointment vehicles |
| US5262164A (en) * | 1989-11-17 | 1993-11-16 | The Procter & Gamble Company | Sustained release compositions for treating periodontal disease |
| US5407663A (en) * | 1991-04-11 | 1995-04-18 | Eisen; Drore | Method of treating inflammatory conditions of the mouth using steroid containing mouthwash which may contain antifungal agents |
| KR960704579A (ko) * | 1993-09-29 | 1996-10-09 | 에드워드 엘. 만델 | 옥시부티닌용 모노글리세리드/락테이트 에스테르 투과 촉진제(Monoglyceride/lactate Ester Permeation Enhancer for Oxybutynin) |
| IL109230A (en) * | 1994-04-05 | 1998-08-16 | Agis Ind 1983 Ltd | Anti-fungal composition containing bifonazole and fluocinonide |
| JPH0948739A (ja) * | 1995-08-04 | 1997-02-18 | Pola Chem Ind Inc | 抗炎症医薬組成物 |
-
1996
- 1996-09-11 GB GBGB9618964.2A patent/GB9618964D0/en active Pending
-
1997
- 1997-09-05 WO PCT/EP1997/004820 patent/WO1998010770A1/fr not_active Ceased
- 1997-09-05 CA CA002266028A patent/CA2266028A1/fr not_active Abandoned
- 1997-09-05 EP EP97919036A patent/EP0973525A1/fr not_active Withdrawn
- 1997-09-05 AU AU43015/97A patent/AU4301597A/en not_active Abandoned
- 1997-09-05 JP JP51322198A patent/JP2001505544A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO1998010770A1 (fr) | 1998-03-19 |
| AU4301597A (en) | 1998-04-02 |
| JP2001505544A (ja) | 2001-04-24 |
| EP0973525A1 (fr) | 2000-01-26 |
| GB9618964D0 (en) | 1996-10-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0951287B1 (fr) | Composition a usage buccal contenant l acide 5-aminosalicylique | |
| CA2633489C (fr) | Compositions et procedes pour le traitement de conditions dermatologiques | |
| CA2268140C (fr) | Preparation pharmaceutique sous forme de gel a appliquer a la surface des muqueuses et des tissus de l'organisme | |
| US5977087A (en) | Topical preparation for treatment of aphthous ulcers and other lesions | |
| CA2000837A1 (fr) | Bases de gel pour composes pharmaceutiques | |
| KR940011240B1 (ko) | 약제학적 피막 형성 조성물 | |
| JPH032126A (ja) | 口腔内抗真菌予防薬およびその使用法 | |
| AU1657201A (en) | Therapeutic compositions and methods of use thereof | |
| US20090169489A1 (en) | Cobalamin compositions and methods for treating or preventing mucositis | |
| JPH10152433A (ja) | 被膜形成性抗真菌剤組成物 | |
| CA2266028A1 (fr) | Compositions buccales contenant du fluocinonure | |
| RU2420257C1 (ru) | Стоматологический гель с хлоргексидином и дибунолом для лечения воспалительных заболеваний пародонта и слизистой оболочки полости рта | |
| KR101333892B1 (ko) | 항진균 조성물 | |
| US20050214230A1 (en) | Novel stomatological gel | |
| JP2000063268A (ja) | 口腔粘膜付着型徐放性錠剤及び歯周疾患治療剤 | |
| US8367683B2 (en) | Composition and method for treatment of warts | |
| US20040101571A1 (en) | Use of hydrogen peroxide for the treatment of warts | |
| JPH0637383B2 (ja) | 口腔用抗炎症剤 | |
| JPH0637379B2 (ja) | 歯周疾患治療用外用剤 | |
| JPH0761933B2 (ja) | 口腔用組成物 | |
| JPH10338633A (ja) | 歯周疾患治療及び予防用組成物 | |
| CN101262848B (zh) | 抗真菌组合物 | |
| TW202135847A (zh) | 口腔內黏膜被覆用抗炎性液狀組成物、及使用其之口內炎之預防及/或治療用醫藥組成物 | |
| JPH09291018A (ja) | 口腔用組成物 | |
| JPH06345630A (ja) | 抗炎症性口腔用組成物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Dead |